

Neehar D Parikh

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5207696/nee-har-d-parikh-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

144
papers

3,478
citations

30
h-index

55
g-index

165
ext. papers

5,093
ext. citations

5.5
avg. IF

6.17
L-index

#	Paper	IF	Citations
144	Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. <i>Gastroenterology</i> , 2018 , 154, 1706-1718.e1	13.3	352
143	Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study. <i>BMJ, The</i> , 2018 , 362, k2817	5.9	317
142	Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 198-210.e2	6.9	143
141	Downstaging hepatocellular carcinoma: A systematic review and pooled analysis. <i>Liver Transplantation</i> , 2015 , 21, 1142-52	4.5	139
140	Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 169-177	6.1	135
139	An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. <i>Hepatology</i> , 2017 , 65, 1196-1205	11.2	123
138	Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 40-47	13.4	90
137	Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. <i>Hepatology</i> , 2017 , 65, 875-884	11.2	86
136	Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 551-559.e1	6.9	81
135	Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. <i>Gastroenterology</i> , 2019 , 156, 1683-1692.e1	13.3	79
134	Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2019 , 157, 1253-1263.e2	13.3	77
133	Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 100, 122-130	4	76
132	Hepatocellular Carcinoma Screening Associated with Early Tumor Detection and Improved Survival Among Patients with Cirrhosis in the US. <i>American Journal of Medicine</i> , 2017 , 130, 1099-1106.e1	2.4	73
131	Projected increase in obesity and non-alcoholic-steatohepatitis-related liver transplantation waitlist additions in the United States. <i>Hepatology</i> , 2019 , 70, 487-495	11.2	69
130	Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database. <i>Hepatology</i> , 2017 , 65, 122-133	11.2	65
129	Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection. <i>Transplantation</i> , 2010 , 89, 222-6	1.8	59
128	Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis. <i>Hepatology</i> , 2020 , 72, 1654-1665	11.2	56

127	Hepatocellular Carcinoma Screening Is Associated With Increased Survival of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 976-987.e4	6.9	51
126	Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma. <i>Cancer</i> , 2017 , 123, 3725-3731	6.4	51
125	A cost-efficacy decision analysis of prophylactic clip placement after endoscopic removal of large polyps. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 1319-24	6.9	50
124	Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta-Analysis. <i>Hepatology</i> , 2021 , 73, 713-725	11.2	50
123	Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 127-137	6.1	44
122	Predictors of Deceased Donor Kidney Discard in the United States. <i>Transplantation</i> , 2017 , 101, 1690-1697.8		41
121	A risk score to predict the development of hepatic encephalopathy in a population-based cohort of patients with cirrhosis. <i>Hepatology</i> , 2018 , 68, 1498-1507	11.2	41
120	Glycoproteomic markers of hepatocellular carcinoma-mass spectrometry based approaches. <i>Mass Spectrometry Reviews</i> , 2019 , 38, 265-290	11	40
119	Primary Care Provider Practice Patterns and Barriers to Hepatocellular Carcinoma Surveillance. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 766-773	6.9	38
118	Biomarker development for hepatocellular carcinoma early detection: current and future perspectives. <i>Hepatic Oncology</i> , 2017 , 4, 111-122	4	35
117	Frailty, Psychoactive Medications, and Cognitive Dysfunction Are Associated With Poor Patient-Reported Outcomes in Cirrhosis. <i>Hepatology</i> , 2019 , 69, 1676-1685	11.2	34
116	Biomarkers for the Early Detection of Hepatocellular Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 2495-2503	4	32
115	Incidence of and Risk Factors for Hepatic Encephalopathy in a Population-Based Cohort of Americans With Cirrhosis. <i>Hepatology Communications</i> , 2019 , 3, 1510-1519	6	31
114	Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis. <i>Gut</i> , 2021 , 70, 401-407	19.2	30
113	Palliative venting percutaneous endoscopic gastrostomy tube is safe and effective in patients with malignant obstruction. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2014 , 28, 1668-73	5.2	30
112	Glycemic control by a glucose management service and infection rates after liver transplantation. <i>Endocrine Practice</i> , 2011 , 17, 546-51	3.2	28
111	Diagnosis of Minimal Hepatic Encephalopathy: A Systematic Review of Point-of-Care Diagnostic Tests. <i>American Journal of Gastroenterology</i> , 2018 , 113, 529-538	0.7	26
110	Projections in donor organs available for liver transplantation in the United States: 2014-2025. <i>Liver Transplantation</i> , 2015 , 21, 855-63	4.5	26

109	Bone mineral density predicts posttransplant survival among hepatocellular carcinoma liver transplant recipients. <i>Liver Transplantation</i> , 2016 , 22, 1092-8	4.5	24
108	Treatment for Advanced Hepatocellular Carcinoma: Current Standard and the Future. <i>Clinical Liver Disease</i> , 2019 , 13, 13-19	2.2	22
107	Introduction to the Liver Imaging Reporting and Data System for Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1228-1238	6.9	22
106	Frequency and Outcomes of Abnormal Imaging in Patients With Cirrhosis Enrolled in a Hepatocellular Carcinoma Surveillance Program. <i>Liver Transplantation</i> , 2019 , 25, 369-379	4.5	22
105	Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices. <i>Current Treatment Options in Gastroenterology</i> , 2017 , 15, 296-304	2.5	21
104	Glycopeptide Biomarkers in Serum Haptoglobin for Hepatocellular Carcinoma Detection in Patients with Nonalcoholic Steatohepatitis. <i>Journal of Proteome Research</i> , 2020 , 19, 3452-3466	5.6	21
103	Glycemic Control Reduces Infections in Post-Liver Transplant Patients: Results of a Prospective, Randomized Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 451-459	5.6	20
102	Incidence and Bedside Predictors of the First Episode of Overt Hepatic Encephalopathy in Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2020 , 115, 2017-2025	0.7	20
101	Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 1397-1405	6.1	19
100	Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early-stage hepatocellular carcinoma: An analysis of SEER-medicare. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2018 , 62, 673-681	1.7	19
99	Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2879-2902.e9	6.9	18
98	Overdiagnosis: An Understudied Issue in Hepatocellular Carcinoma Surveillance. <i>Seminars in Liver Disease</i> , 2017 , 37, 296-304	7.3	18
97	New Labyrinth Microfluidic Device Detects Circulating Tumor Cells Expressing Cancer Stem Cell Marker and Circulating Tumor Microemboli in Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2019 , 9, 18575	4.9	18
96	Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms. <i>American Journal of Gastroenterology</i> , 2020 , 115, 1642-1649	0.7	17
95	Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda. <i>Clinical Gastroenterology and Hepatology</i> , 2020 ,	6.9	17
94	The Quality and Outcomes of Care Provided to Patients with Cirrhosis by Advanced Practice Providers. <i>Hepatology</i> , 2020 , 71, 225-234	11.2	17
93	Development and validation of a symptom index for advanced hepatobiliary and pancreatic cancers: the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy (NCCN-FACT) Hepatobiliary-Pancreatic Symptom Index (NFHSI). <i>Cancer</i> , 2012 , 118, 5997-6004	6.4	16
92	Model for end-stage liver disease exception points for treatment-responsive hepatocellular carcinoma. <i>Clinical Liver Disease</i> , 2016 , 7, 97-100	2.2	16

91	Body Composition Features Predict Overall Survival in Patients With Hepatocellular Carcinoma. <i>Clinical and Translational Gastroenterology</i> , 2016 , 7, e172	4.2	16
90	Quality of life, risk assessment, and safety research in liver transplantation: new frontiers in health services and outcomes research. <i>Current Opinion in Organ Transplantation</i> , 2012 , 17, 241-7	2.5	14
89	Benefits and Harms of Hepatocellular Carcinoma Surveillance in a Prospective Cohort of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1925-1932.e1	6.9	13
88	Body Composition Predicts Survival in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. <i>Cancer Research and Treatment</i> , 2018 , 50, 530-537	5.2	13
87	Reinterpretation of Outside Hospital MRI Abdomen Examinations in Patients With Cirrhosis: Is the OPTN Mandate Necessary?. <i>American Journal of Roentgenology</i> , 2016 , 207, 782-788	5.4	12
86	Reduced Incidence of Hepatic Encephalopathy and Higher Odds of Resolution Associated With Eradication of HCV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1197-1206.e7	6.9	12
85	Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1520-1530	6.9	12
84	Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 974-983	6.9	12
83	Risk Assessment of Hepatocellular Carcinoma in Patients with Hepatitis C in China and the USA. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 3243-3253	4	11
82	A Comparison of Staging Systems for Hepatocellular Carcinoma in a Multicenter US Cohort. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 781-782	6.9	11
81	Natural history of ROHHAD syndrome: development of severe insulin resistance and fatty liver disease over time. <i>Clinical Diabetes and Endocrinology</i> , 2019 , 5, 9	4.7	11
80	HCC Surveillance Improves Early Detection, Curative Treatment Receipt, and Survival in Patients with Cirrhosis: A Systematic Review and Meta-Analysis.. <i>Journal of Hepatology</i> , 2022 ,	13.4	11
79	Identifying Patients With Hepatic Encephalopathy Using Administrative Data in the ICD-10 Era. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 604-606.e1	6.9	11
78	Patient Preferences for Hepatocellular Carcinoma Surveillance Parameters. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	11
77	Hepatocellular carcinoma surveillance, early detection and survival in a privately insured US cohort. <i>Liver International</i> , 2020 , 40, 947-955	7.9	10
76	Dynamic Changes in Ultrasound Quality for Hepatocellular Carcinoma Screening in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	10
75	Radiologist Quality Assurance by Nonradiologists at Tumor Board. <i>Journal of the American College of Radiology</i> , 2018 , 15, 1259-1265	3.5	10
74	Evaluation of AGP Fucosylation as a Marker for Hepatocellular Carcinoma of Three Different Etiologies. <i>Scientific Reports</i> , 2019 , 9, 11580	4.9	9

73	Estimated Association Between Organ Availability and Presumed Consent in Solid Organ Transplant. <i>JAMA Network Open</i> , 2019 , 2, e1912431	10.4	9
72	GALAD Demonstrates High Sensitivity for HCC Surveillance in a Cohort of Patients with Cirrhosis. <i>Hepatology</i> , 2021 ,	11.2	9
71	Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C in China and the United States. <i>Scientific Reports</i> , 2020 , 10, 20922	4.9	9
70	#LiverTwitter: An Emerging Tool for Liver Education and Research. <i>Hepatology Communications</i> , 2020 , 4, 1229-1233	6	9
69	Association Between Race/Ethnicity and Insurance Status with Outcomes in Patients with Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 1669-1678	4	9
68	Natural history of hepatocellular carcinoma after stereotactic body radiation therapy. <i>Abdominal Radiology</i> , 2020 , 45, 3698-3708	3	9
67	Population-Based Analysis and Projections of Liver Supply Under Redistricting. <i>Transplantation</i> , 2017 , 101, 2048-2055	1.8	8
66	Doylestown Plus and GALAD Demonstrate High Sensitivity for HCC Detection in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	8
65	A Panel of Glycopeptides as Candidate Biomarkers for Early Diagnosis of NASH Hepatocellular Carcinoma Using a Stepped HCD Method and PRM Evaluation. <i>Journal of Proteome Research</i> , 2021 , 20, 3278-3289	5.6	8
64	Rationale and design of the Hepatocellular carcinoma Early Detection Strategy study: A multi-center longitudinal initiative of the National Cancer Institute@ Early Detection Research Network. <i>Contemporary Clinical Trials</i> , 2019 , 76, 49-54	2.3	8
63	Hepatotoxicity and drug interactions in liver transplant candidates and recipients. <i>Clinics in Liver Disease</i> , 2013 , 17, 737-47, x-xi	4.6	7
62	Treatment Patterns and Economic Burden by Lines of Therapy Among Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy. <i>Journal of Gastrointestinal Cancer</i> , 2020 , 51, 217-226	1.6	7
61	Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 890-901	6.1	7
60	Controversies in criteria for liver transplantation in hepatocellular carcinoma. <i>Current Opinion in Gastroenterology</i> , 2016 , 32, 182-8	3	6
59	Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians. <i>Pharmacoeconomics</i> , 2020 , 38, 5-24	4.4	6
58	Falls are common, morbid, and predictable in patients with cirrhosis. <i>Journal of Hepatology</i> , 2021 , 75, 582-588	13.4	6
57	INPATIENT HYPOGLYCEMIC EVENTS IN A COMPARATIVE EFFECTIVENESS TRIAL FOR GLYCEMIC CONTROL IN A HIGH-RISK POPULATION. <i>Endocrine Practice</i> , 2016 , 22, 1040-7	3.2	5
56	Clinical outcomes and quality of life in recipients of livers donated after cardiac death. <i>Gastroenterology Research and Practice</i> , 2015 , 2015, 680316	2	5

55	PRM-MS Quantitative Analysis of Isomeric -Glycopeptides Derived from Human Serum Haptoglobin of Patients with Cirrhosis and Hepatocellular Carcinoma. <i>Metabolites</i> , 2021 , 11,	5.6	5
54	Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma. <i>Journal of Comparative Effectiveness Research</i> , 2021 , 10, 343-352	2.1	5
53	The ITA.LI.CA Staging System: A Novel Staging System for Hepatocellular Carcinoma. <i>PLoS Medicine</i> , 2016 , 13, e1002005	11.6	4
52	Hepatocellular Carcinoma Screening Process Failures in Patients with Cirrhosis. <i>Hepatology Communications</i> , 2021 , 5, 1481-1489	6	4
51	Individualized Adaptive Radiation Therapy Allows for Safe Treatment of Hepatocellular Carcinoma in Patients With Child-Turcotte-Pugh B Liver Disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 109, 212-219	4	4
50	Assessment of National Organ Donation Rates and Organ Procurement Organization Metrics. <i>JAMA Surgery</i> , 2021 , 156, 173-180	5.4	4
49	TNFR1 and the TNF α axis as a targetable mediator of liver injury from stereotactic body radiation therapy. <i>Translational Oncology</i> , 2021 , 14, 100950	4.9	4
48	Frontiers of therapy for hepatocellular carcinoma. <i>Abdominal Radiology</i> , 2021 , 46, 3648-3659	3	3
47	A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis. <i>Med</i> , 2021 , 2, 836-850.e10	31.7	3
46	Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium. <i>Gastroenterology</i> , 2021 , 161, 1502-1512	13.3	3
45	Reply. <i>Hepatology</i> , 2017 , 66, 1002-1003	11.2	2
44	Outcome of Hepatocellular Carcinoma Detected During Surveillance: Comparing USA and Japan. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 2379-2388.e6	6.9	2
43	A colorectal cancer screening program in an underserved, ethnically diverse population in Chicago, IL. <i>Journal of Community Health</i> , 2013 , 38, 603-8	4	2
42	Heparin-induced thrombocytopenia testing is over-utilized in cirrhosis & correlates with poor clinical outcomes. <i>Annals of Hepatology</i> , 2014 , 13, 548-554	3.1	2
41	Phase II study of individualized adaptive stereotactic body radiotherapy (SBRT) for patients at high risk for liver damage.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 424-424	2.2	2
40	Hepatocellular Carcinoma Surveillance and Staging. <i>Molecular and Translational Medicine</i> , 2019 , 27-51	0.4	2
39	EUS-guided gastrojejunal anastomosis to facilitate endoscopic retrograde cholangiography in a patient with a right lobe liver transplant and Roux-en-Y anatomy. <i>VideoGIE</i> , 2020 , 5, 473-475	1.1	2
38	Comprehensive Health-State Utilities in Contemporary Patients With Cirrhosis. <i>Hepatology Communications</i> , 2020 , 4, 852-858	6	2

37	Radiation Therapies for the Treatment of Hepatocellular Carcinoma. <i>Clinical Liver Disease</i> , 2021 , 17, 341-346	2	2
36	Outcomes of Patients With Cirrhosis Undergoing Orthopedic Procedures: An Analysis of the Nationwide Inpatient Sample. <i>Journal of Clinical Gastroenterology</i> , 2019 , 53, e356-e361	3	2
35	Recent Advances in Hepatocellular Carcinoma Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 2020-2024	6.9	2
34	Liquid Biopsy for Hepatocellular Carcinoma. <i>Current Hepatology Reports</i> , 2019 , 18, 390-399	1	1
33	PRO: Hepatocellular Carcinoma Surveillance: A Useful Tool Against the Rising Tide of HCC. <i>American Journal of Gastroenterology</i> , 2017 , 112, 1632-1633	0.7	1
32	The Magnitude of the Health and Economic Impact of Increased Organ Donation on Patients With End-Stage Renal Disease.. <i>MDM Policy and Practice</i> , 2021 , 6, 23814683211063418	1.5	1
31	Stereotactic body radiotherapy (SBRT) as an alternative to transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4087-4087	2.2	1
30	Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2021 ,	11.2	1
29	Accuracy of International Classification of Diseases-10 Codes for Cirrhosis and Portal Hypertensive Complications. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	1
28	Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters using the Modified RAND/UCLA Delphi Process. <i>Cancers</i> , 2020 , 12,	6.6	1
27	Imaging of treatment response during systemic therapy for hepatocellular carcinoma. <i>Abdominal Radiology</i> , 2021 , 46, 3625-3633	3	1
26	Management of early hepatocellular carcinoma: results of the Delphi consensus process of the Americas Hepato-Pancreato-Biliary Association. <i>Hpb</i> , 2021 , 23, 753-761	3.8	1
25	Alcohol Policies and Alcohol-related Liver Disease Mortality. <i>Gastroenterology</i> , 2021 , 161, 350-352	13.3	1
24	The Future of Quality Improvement for Cirrhosis. <i>Liver Transplantation</i> , 2021 , 27, 1479-1489	4.5	1
23	Comparison of Seven Noninvasive Models for Predicting Decompensation and Hospitalization in Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 4508-4517	4	1
22	Development of a Predictive Model for Deceased Donor Organ Yield. <i>Transplantation</i> , 2018 , 102, e364	1.8	1
21	Inpatient Gastroenterology Consultation and Outcomes of Cirrhosis-Related Hospitalizations in Two Large National Cohorts. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	1
20	A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCC. <i>Hepatology Communications</i> , 2021 , 5, 538-547	6	1

19	A Fucosylated Glycopeptide as a Candidate Biomarker for Early Diagnosis of NASH Hepatocellular Carcinoma Using a Stepped HCD Method and PRM Evaluation.. <i>Frontiers in Oncology</i> , 2022 , 12, 818001	5.3	1
18	Deprescribing zolpidem reduces falls and fractures in patients with cirrhosis.. <i>JHEP Reports</i> , 2022 , 4, 100478	4.7	1
17	Risk of Hepatocellular Carcinoma in Patients with Indeterminate (LI-RADS 3) Liver Observations.. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	1
16	Glycopeptides with Sialyl Lewis Antigen in Serum Haptoglobin as Candidate Biomarkers for Nonalcoholic Steatohepatitis Hepatocellular Carcinoma Using a Higher-Energy Collision-Induced Dissociation Parallel Reaction Monitoring-Mass Spectrometry Method. <i>ACS Omega</i> ,	3.9	1
15	Heparin-induced thrombocytopenia testing is over-utilized in cirrhosis & correlates with poor clinical outcomes. <i>Annals of Hepatology</i> , 2014 , 13, 548-54	3.1	0
14	Hepatocellular Carcinoma-Related Mortality in the USA, 1999-2018.. <i>Digestive Diseases and Sciences</i> , 2022 , 1	4	0
13	Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States.. <i>Journal of Hepatology</i> , 2022 ,	13.4	0
12	Changes in Liver Transplant Criteria for Hepatocellular Carcinoma. <i>Current Hepatology Reports</i> , 2017 , 16, 33-38	1	
11	Reply. <i>Gastroenterology</i> , 2020 , 158, 1844	13.3	
10	Reply. <i>Hepatology</i> , 2017 , 66, 679-680	11.2	
9	ANOVA models for Brownian motion. <i>Communications in Statistics - Theory and Methods</i> , 2017 , 46, 7642-7660	7.6	
8	Response to Sage and Mogrovejo. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1688-9	0.7	
7	Consensus treatment guidelines for urgent symptoms in cholangiocarcinoma (CC) patients (pts) with biliary stents or catheters using the modified RAND/UCLA Delphi process.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 452-452	2.2	
6	Author response to Letter to the Editor: Chronological change in alpha-foetoprotein levels in hepatocellular carcinoma after eradication of hepatitis C virus <i>Liver International</i> , 2020 , 40, 2307	7.9	
5	REPLY. <i>Hepatology</i> , 2021 , 74, 1715	11.2	
4	A machine learning approach for the prediction of overall deceased donor organ yield. <i>Surgery</i> , 2021 , 170, 1561-1567	3.6	
3	Oral simethicone tablets with PEG-ELS split-prep reduces frequency of inadequate bowel cleansing and decreases bubbles. <i>GastroHep</i> , 2021 , 3, 254-260	1	
2	Attacking Alcohol-Related Liver Disease by Taxing Alcohol Sales. <i>Alcoholism: Clinical and Experimental Research</i> , 2021 , 45, 51-53	3.7	

- 1 Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans.. *Digestive Diseases and Sciences*, **2022**, 1

4